Company Profile

Kala Pharmaceuticals Inc (AKA: Hanes Newco, Inc)
Profile last edited on: 2/28/23      CAGE: 5VRP4      UEI: ZKCRJ776A5V6

Business Identifier: Innovative therapies for rare eye diseases
Year Founded
2009
First Award
2011
Latest Award
2011
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 Beaver Street Suite 201
Waltham, MA 02452
   (781) 996-5252
   info@kalarx.com
   www.kalarx.com
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Very briefly SBIR-involved from soon after its founding, Kala Pharmaceuticals (NASDAQ: KALA) went public in July 2017. The firm is a clinical-stage biopharmaceutical company structured around research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received orphan drug designation from the U.S. Food and Drug Administration. Kala is also targeting the potential development of KPI-012 for the treatment of Partial Limbal Stem Cell Deficiency and ocular manifestations of moderate-to-severe Sjögren's and plans to initiate preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative di

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
150-249
Revenue Range
15M-20M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : KALA
IP Holdings
75-99

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Robert Paull -- Acting CEO

  Guillaume Pfefer -- President and CEO

  Kim Brazzell -- Chief Medical Officer

  Colin Gardner -- Co-Founder

  Justin Hanes -- Co-Founder

  Charlie McDermott -- EVP Business Development

  Winston Ong

  Kayla Parcells

  Kevin Pojasek -- VP Corporate Development

  Eric Trachtenberg -- General Counsel, Chief Compliance Officer & Corporate Secretar